Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data

doi:10.3748/wjg.v22.i44.9829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 44

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6353)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

349

WORD

169

HTML

2711

Tables (1-5)

253

Sum=3482

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

993

Download

1878

Sum=2871

Nov 28, 2016 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Nov 28, 2016; 22(44): 9829-9835
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9829

Table 5 Patients known to the Regional Health Agency of Tuscany treated with pegylated interferon + ribavirin and/or direct-acting antiviral drugs

Genotypes	HCV patients treated with PEGINF + Rib	Sustained virological responders to PEGINF + Rib	Elegible patients to DAAs	HCV patients treated with DAAs	Sustained virological responders¹ to DAAs
1b (60%)	4516	2075	2445
1a (6%)	452
2c (20%)	1505	1075	364	1996	1896
3a (6%)	452	271	151		(about 95% SVR)
4a/d (8%)	603	247	300
Totale	7528	3668	3260

¹HCV is considered regardless of genotypes. Sustained virological responders and total number of patients based on genotype - Source: Regional Health Agency of Tuscany and prevalence data by Marcellin et al[8]. PEGINF: Pegylated Interferon; RBV: Ribavirin; DAAs: Direct-acting antiviral drugs.

Citation: Silvestri C, Bartolacci S, Pepe P, Monnini M, Voller F, Cipriani F, Stasi C. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data. World J Gastroenterol 2016; 22(44): 9829-9835
URL: https://www.wjgnet.com/1007-9327/full/v22/i44/9829.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i44.9829